Rezolute reports Q4 and FY 2026 financial results and upLIFT study interim data
Rezolute released late FY26 results and positive interim onLIFT trial data, though the congenital HI program missed its primary endpoint, the company stated trial results remain under FDA review.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed